Purpose: To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed-time-point 2- F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective 18 F-FDG-PET scans at time points 1 (45-60 minutes after tracer injection, TP1) and 2 (100-150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV max (maximum standardized uptake values) ratios were also assessed. Results: F-FDG-PET at TP2. Lesion-to-liver and lesionto-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). Conclusions: Delayed-time-point imaging may improve 18 F-FDG-PET in MALT lymphoma.
1 This is because MALT lymphoma has previously shown a variable FDG-avidity: whereas in most studies, MALT lymphoma was FDG-avid in 54% to 82% of the patients, 2 the largest and most recent study reported FDG avidity in only 28% of MALT lesions. 3 Delayed-time-point 18 F-FDG-PET has been reported to improve the sensitivity of 18 F-FDG-PET for different malignancies, 4 including cholangiocarcinoma and lung cancer. 5, 6 Whereas one previous study used dual-time-point 18 F-FDG-PET in lymphoma, and observed higher standardized uptake values (SUVs) two hours after tracer injection, 7 delayed-time-point 18 F-FDG-PET has not been evaluated in MALT lymphomas as yet, despite the potential implications for patient management.
It was, therefore, the goal of our study to determine whether in patients with MALT lymphoma, delayed-time-point 18 F-FDG-PET yields the following: (1) a higher detection rate, and (2) a higher lesion-to-liver or lesion-to-blood contrast, than standard-time-point 18 F-FDG-PET performed 45 to 60 minutes after tracer injection.
MATERIALS AND METHODS
The present study was part of a prospective, institutional review board-approved trial that compared PET/CT and PET/ magnetic resonance imaging (PET/MR), in oncologic patients who were referred to the local tertiary care center for staging and follow-up. Patients who gave written informed consent underwent 18 F-FDG-PET/CT, and, directly after it, 18 F-FDG-PET/MR, using a single tracer injection.
For the present study, only patients with previously untreated MALT lymphoma, as verified by a reference pathologist who analyzed tissue samples obtained by biopsy or surgery, according to the World Health Organization classification of hematological and lymphoid malignancies, were included. Pregnancy, general contraindications to MRI (eg, implantable medical devices, claustrophobia), elevated glucose levels (>150 mg/dL), and known adverse reactions to ionized contrast media, comprised the exclusion criteria.
Imaging Protocols
First, 18 F-FDG-PET/CTwas performed from the vertex to the upper thigh (head-first, in craniocaudal direction), using a 64-row multidetector hybrid system (Biograph TruePoint 64; Siemens, Erlangen, Germany), with an axial field of view (FOV) of 216 mm and a PET sensitivity of 7.6 counts per second /kBq. Patients fasted for 5 hours before imaging. Positron emission tomography (PET) was performed 45 to 60 minutes after an intravenous administration of 300 MBq of 18 F-FDG (time point 1 [TP1]), with 3-minuteper-bed position, 4 iterations, and 21 subsets, a 5-mm slice thickness, and a 168 Â 168 matrix, using the point-spread-function (PSF)-based reconstruction algorithm TrueX. Computed tomographic maps were used for attenuation correction. Venous-phase contrast-enhanced CT was obtained after the intravenous injection of 100 mL of a tri-iodinated, nonionic contrast medium at a rate of 2 mL/s; a tube voltage of 120 kV, a tube current of 230 mA, a collimation of 64 Â 0.6 mm, a 3-mm slice thickness at a 2-mm increment, and a 512 Â 512 matrix.
Directly after the PET/CT, 18 F-FDG-PET/MR was performed, covering the same anatomy (head first, in craniocaudal direction), and using a fully integrated 3-T system (Biograph mMR; Siemens, Erlangen, Germany) with high-performance gradient systems (45 mT/m), a slew rate of 200 T/m per second, and equipped with a phased-array body coil. The system offers an axial field of view (FOV) of 258 mm, and a sensitivity of 13.2 counts per second/kBq, for PET.
18
F-FDG-PET was performed 100-150 minutes after the original, intravenous tracer administration (time point 2, TP2), with 5-minute per bed position, 3 iterations, and 21 subsets, a 4.2-mm slice thickness, and a 172 Â 172 matrix, using the PSFbased reconstruction algorithm HD-PET. Two axial, two-point, Dixon, 3-dimensional, volume-interpolated T1-weighted breathhold MR sequences were acquired for attenuation correction (AC), and for anatomic correlation, using the following parameters: repetition time (TR)/echo times (TE), 4.02 (AC, 3.6) ms/1.23, 2.46 ms; one average, two echoes; flip angle, 10 degrees; matrix, 320 Â 175 (AC, 192 Â 79); FOV, 430 Â 309 (AC, 328 Â 500) mm; and slice thickness, 3 mm with a 0.6-mm gap. A single-shot, echoplanar imaging (EPI)-based, spectral adiabatic inversion recovery diffusion-weighted imaging (DWI) sequence was obtained with the following parameters: b values, 50 and 800; TR/TE, 6800/ 63 ms; 6 averages and one echo; flip angle, 180 degrees; matrix, 168 Â 104; FOV, 440 Â340 mm; slice thickness, 6-mm, with a 1.2-mm gap.
No diuretic or spasmolytic medications for improved evaluation of the urinary tract/bladder or gastrointestinal tract were administered before PET/CT or PET/MR.
Lymphoma Detectability
A board-certified nuclear medicine physician and a boardcertified radiologist rated all images in consensus. The 14 nodal regions defined at the Rye symposium (right/left cervical; right/left axillary; right/left infraclavicular; mediastinal; hilar; mesenteric; para-aortic; right/left pelvic; and right/left inguinal), 8 and 12 extranodal regions were evaluated: Waldeyer ring: lungs; liver; spleen; stomach; small intestine; large intestine; right and left kidney; bones; soft tissues (skin/fat/muscle); and other organs/tissues (e.g., lacrimal glands). On both the 18 F-FDG-PET of the PET/CT at TP1, and the 18 F-FDG-PETof the PET/MR at TP2 (which was evaluated separately, and blinded to the TP1 results), nodal and extranodal regions were rated as involved when there was at least one focal (or, for bone marrow, also diffuse) area of increased tracer accumulation relative to the surrounding tissue. The spleen was rated as positive if nodular or diffuse tracer uptake higher than that in the liver was observed.
Lesion-to-Liver and Lesion-to-Blood Contrast
After the independent lesion assessment at TP1 and TP2, quantitative analysis was performed, this time with access to histology and DWI. Maximum and mean SUVs (SUV max , SUV mean ) on 18 F-FDG-PETwere measured for up to 3 largest, previously identified lymphoma manifestations of each patient at TP1 and TP2 based on isocontour volumes of interest (VOIs) that included all voxels greater than 50% of the SUV max of each lesion. For a lesion that was only visible on 18 F-FDG-PET at one time point, the VOI was copied from the PET that visualized the lesion to the other PET. For lymphoma lesions that were not visible on 18 F-FDG-PET at either time point but were visible on DWI, which has high sensitivity for MALT lymphoma, 9 lesion contours were defined manually on DWI, provided that the lesion(s) had been confirmed by histology. SUV max and SUV mean were also measured in the lesion-free liver parenchyma and the mediastinal blood pool (ie, aortic arch), using spherical VOIs with diameters of 3 cm (liver) and 1.5 cm (blood pool).
Statistical Analysis
Histology was the basis for the reference standard and was required for all extranodal lymphoma manifestations. For suspected lymph node involvement, histological verification in at least a single nodal region was required; in case of involvement of multiple nodal regions, positive F-FDG-PET at one time point with DWI, was used as the reference standard. This strategy was chosen because it was regarded as clinically infeasible, as well as unethical, to verify regions that are negative at imaging by biopsy/histology.
Region-based sensitivity and specificity as well as patientbased sensitivity (but not specificity because only patients with histologically proven MALT lymphoma in at least one region were included in this study), as well as their respective 95% confidence intervals (CI), were calculated for 18 F-FDG-PET at TP1, and for 18 F-FDG-PET at TP2. Patient-based lesion-to-liver and lesionto-blood ratios of SUV max and SUV mean values were calculated separately at TP1 and TP2 and were compared using paired t tests (using arithmetic means in patients with >1 lesion). The specified level of significance was P ≤ 0.05.
RESULTS
Thirteen patients (eight women and 5 men; mean age, 66.8 ± 14.3 years) with 23 lymphoma manifestations met our criteria for participation in the study (Table 1 ). All 21 histologically proven lymphoma manifestations underwent biopsy before the With regard to lesion-to-liver and lesion-to-blood SUV max ratios, significant differences were observed between 18 F-FDG-PET at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) and 18 F-FDG-PET at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10) (P = 0.003 and P = 0.001). The lesion-to-blood, and lesion-to-liver SUV mean ratios also differed significantly between 18 F-FDG-PET at TP1 (ratios, 1.11 ± 0.40 and 1.38 ± 0.54) and 18 F-FDG-PET at TP2 (ratios, 1.77 ± 1.22 and 2.32 ± 1.26) (P = .035 and P = 0.006).
DISCUSSION
Our observations suggest that in untreated MALT lymphoma, the performance of 18 F-FDG-PET may indeed improve when PET is performed after an extended time interval, ie, approximately 2 hours after radiotracer injection. Notably, 3 of 13 patients, which were (completely) false negative on PET at TP1 (the standard time point), were true positive at TP2 (ie, the delayed time point; Figs. 1 and 2) .
Lesion-to-liver as well as lesion-to-blood contrast of MALT lymphomas on 18 F-FDG-PET was significantly higher at TP2 than at TP1, regardless of whether SUV max or SUV mean were used. This seems plausible because several malignant tumors show a prolonged uptake of FDG, with higher SUV max values on delayed 18 F-FDG-PET 4, 6 ; in addition, the high glucose-6-phosphatase activity of the liver leads to an early peak followed by a decrease in intracellular FDG retention, and the blood pool clearance of 18 F-FDG increases over time. 4, 10 A combination of these factors is the most likely explanation for our own findings. 
